Skip to main content

Production of cheaper alternatives to name brand obesity drugs will stop on Wednesday

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.
Why you can trust KUOW

Recommended Stories

Get Local Stories

Delivered to your inbox daily, weekly, or monthly.

Explore Newsletters